Results 21 to 30 of about 7,000 (133)

Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of cytomegalovirus (CMV) infection.
Eun Jeong Ko, Ji Hyun Yu, Chul Woo Yang, Byung Ha Chung   +3 more
doaj   +1 more source

Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection

Инфекция и иммунитет, 2020
Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and ...
V. A. Zurochka, O. I. Zabkov, M. A. Dobrynina, V. F. Gritsenko, E. V. Davydova, A. V. Chukichev, N. A. Zabokritskii, A. P. Sarapultsev, A. V. Zurochka   +8 more
doaj   +1 more source

VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Herpes simplex virus (HSV) may be involved in Alzheimer's disease (AD) pathophysiology. The antiviral valacyclovir inhibits HSV replication. Methods This phase‐II pilot trial involved valacyclovir administration (thrice daily, 500 mg week 1,
Bodil Weidung, Eva‐Stina Hemmingsson, Jan Olsson, Torbjörn Sundström, Kaj Blennow, Henrik Zetterberg, Martin Ingelsson, Fredrik Elgh, Hugo Lövheim   +8 more
doaj   +1 more source

Viral Retinitis with Co-Infection Cytomegalovirus and Varicella Zoster

Delhi Journal of Ophthalmology, 2023
Combined infection with cytomegalovirus (CMV) and varicella-zoster virus (VZV) is a rare entity, especially in an immunocompetent person. Almost all cases with co-infection are either immunocompromised or on immunosuppressant. Here, we present to you one
Dhaivat Shah, Ravin Punamia, Bennet Chacko Mathew, Rahul Singh, Milind Rokade   +4 more
doaj   +1 more source

Valacyclovir induced neurotoxicity, with therapeutic drug monitoring, in a hospital-based setting in the Netherlands

European Journal of Case Reports in Internal Medicine
Background: Valacyclovir-induced neurotoxicity is a rare side effect. The aim of this study was to perform a retrospective analysis of patients with valacyclovir-induced neurotoxicity and establish valacyclovir plasma concentrations in a tertiary ...
Job F.H. Eijsink, Joost N. Udo, Daan J. Touw, Bart J. Dekkers   +3 more
doaj   +1 more source

Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes.
Miguel A. Aristizabal‐Torres, Jessi M. Larrinaga, Katherine Bodiford, Olayemi Sokumbi, Leila Tolaymat   +4 more
wiley   +1 more source

Effectiveness of Amenamevir Vs. Valacyclovir in Preventing Herpes Zoster‐Related Hospitalization and Complications: A Target Trial Emulation Using a Large Japanese Claims Database

The Journal of Dermatology, EarlyView.
ABSTRACT Amenamevir is a novel anti‐herpes zoster drug that is increasingly used in Japan because of its once‐daily administration and lack of renal dose adjustment requirements. However, evidence of its clinical effectiveness is limited. This study aimed to estimate the clinical effectiveness of amenamevir vs. valacyclovir in preventing zoster‐related
Yasuhiro Kano, Yuya Kimura, Hideo Yasunaga   +2 more
wiley   +1 more source

Valacyclovir Neurotoxicity and Nephrotoxicity in an Elderly Patient Complicated by Hyponatremia

Drug Target Insights, 2018
A 66-year-old women with no history of renal disease was admitted due to a coma and acute kidney injury with a serum creatinine level of 7.44 mg/dL which were ascribed to valacyclovir neurotoxicity and nephrotoxicity, respectively.
Takuya Murakami, Tetsu Akimoto, Mari Okada, Erika Hishida, Taro Sugase, Atsushi Miki, Marina Kohara, Hiromichi Yoshizawa, Takahiro Masuda, Takahisa Kobayashi, Osamu Saito, Shigeaki Muto, Daisuke Nagata   +12 more
doaj   +2 more sources

Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin–Angiotensin System Inhibitors: The Detection of Signals of Drug–Drug Interactions

Frontiers in Pharmacology, 2019
Background: Drug-related acute kidney disease is a common side effect of valacyclovir (VACV) treatment. Although analgesics are frequently administered concomitantly with VACV to treat the pain of herpes zoster, the differences between nonsteroidal anti ...
Ichiro Inaba, Ichiro Inaba, Yuki Kondo, Shinya Iwasaki, Satoko Tsuruhashi, Ayano Akaishi, Kazuya Morita, Kentaro Oniki, Junji Saruwatari, Yoichi Ishitsuka, Tetsumi Irie, Tetsumi Irie   +11 more
doaj   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source